<DOC>
	<DOCNO>NCT01603069</DOCNO>
	<brief_summary>This study AZD3241 placebo give patient Parkinson 's disease blind randomized assignment . The main objective see safety tolerability drug acceptable .</brief_summary>
	<brief_title>A Study Assess Safety Tolerability Oral AZD3241 Patients With Parkinson 's Disease</brief_title>
	<detailed_description>A Phase IIa , 12 Week , Multicentre , Double-Blind , Randomized , Placebo-Controlled , Parallel-Group Study Assess Safety Tolerability Oral AZD3241 Patients Parkinson 's Disease</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Each patient must able willing provide sign date informed consent prior study . Female male patient age 30 80 year day enrollment ( Visit 1 ) . Patients must meet criterion `` Diagnosis idiopathic Parkinson 's disease '' accord UKPDS Brain Bank criterion ( Hughes et al 1992 ) . Have modify Hoehn Yahr stage 12.5 . Having treatment Parkinson 's disease need add antiParkinson 's disease treatment 14 week study OR stable antiParkinson 's disease medication . Diagnosis unclear suspicion Parkinsonian syndromes exists , secondary Parkinsonism ( cause drug , toxin , infectious agent , vascular disease , trauma , brain neoplasm ) , Parkinsonplus syndromes heredodegenerative disease . Have undergone surgery treatment Parkinson 's disease ( eg , pallidotomy , deep brain stimulation , fetal tissue transplantation ) undergone brain surgery time , even nonParkinson 's disease condition . Presence dyskinesia , motor fluctuation , swallow difficulty loss postural reflex , define score 2 item 30 UPDRS . Current/history psychiatric diagnosis acute psychotic disorder primary psychiatric diagnosis , i.e . bipolar disorder MDD , psychiatric , neurological behavioral disorders/symptoms may interfere conduct study . Current significant major unstable respiratory disease , heart disease , cerebrovascular disease , hematological disease , hepatic disease , renal disease , gastrointestinal ( GI ) disease , major disease judge investigator .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
</DOC>